<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02120664</url>
  </required_header>
  <id_info>
    <org_study_id>18F-AV-45-A22</org_study_id>
    <nct_id>NCT02120664</nct_id>
  </id_info>
  <brief_title>Florbetapir Calibration to the Centiloid Scale</brief_title>
  <official_title>A Multicenter, Multicountry Study to Calibrate Florbetapir (18F) PET Imaging Data to the Centiloid Scale Based on 11C-PiB</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avid Radiopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avid Radiopharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to demonstrate the conversion of florbetapir (18F) Positron Emission
      Tomography (PET) Standard Uptake Value ratio (SUVr) to Centiloid units.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Florbetapir SUVr Conversion to Centiloid Units</measure>
    <time_frame>up to 70 minutes post injection</time_frame>
    <description>Conversion of florbetapir (18F) positron emission tomography (PET) standard uptake value ratio (SUVr) to Centiloid units. The Centiloid is anchored at values of 0 and 100 corresponding to the median Pittsburgh Compound B (11C-PiB) SUVr value for a representative group of young (&lt;45) cognitively and medically healthy control subjects (YHC) and the median SUVr value for a representative group of 11C-PiB positive patients diagnosed with Alzheimer's disease, respectively. A cortical average to cerebellum SUVr was used for this outcome measure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of Florbetapir (18F) Centiloid and 11C-PiB Centiloid</measure>
    <time_frame>up to 70 minutes post injection</time_frame>
    <description>Correlation coefficient between 11C-PiB and florbetapir (18F) SUVr as converted to centiloid units. The Centiloid is anchored at values of 0 and 100 corresponding to the median Pittsburgh Compound B (11C-PiB) SUVr value for a representative group of young (&lt;45) cognitively and medically healthy control subjects (YHC) and the median SUVr value for a representative group of 11C-PiB positive patients diagnosed with Alzheimer's disease, respectively. A cortical average to cerebellum SUVr was used for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variability of PET Images in Young Healthy Control Subjects.</measure>
    <time_frame>up to 70 minutes post injection</time_frame>
    <description>Coefficient of variation for 11C-PiB and florbetapir (18F) SUVr. A cortical average to cerebellum SUVr was used for this outcome measure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Amyloid Negative Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 10 cognitively normal young subjects will receive a single i.v. bolus injection of approximately 370 megabecquerel (MBq) (10 millicurie [mCi]) florbetapir (18F) and a single i.v. bolus injection of approximately 555 MBq (15 mCi) 11C-PiB.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amyloid Positive Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 25 subjects with a range of amyloid density comprised of subjects clinically diagnosed with Alzheimer's Disease (AD) and subjects at risk for elevated amyloid density will receive a single i.v. bolus injection of approximately 370 MBq (10 mCi) florbetapir (18F) and a single i.v. bolus injection of approximately 555 MBq (15 mCi) 11C-PiB.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Florbetapir (18F)</intervention_name>
    <arm_group_label>Amyloid Negative Subjects</arm_group_label>
    <arm_group_label>Amyloid Positive Subjects</arm_group_label>
    <other_name>Florbetapir F 18</other_name>
    <other_name>Amyvid</other_name>
    <other_name>18F-AV-45</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>11C-PiB</intervention_name>
    <arm_group_label>Amyloid Negative Subjects</arm_group_label>
    <arm_group_label>Amyloid Positive Subjects</arm_group_label>
    <other_name>Pittsburgh Compound B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cognitively Normal Subjects

               -  Males or females ≥ 21 and ≤ 45 years of age

               -  Mini-mental state examination (MMSE) ≥ 29

          -  Clinically Diagnosed AD Subject

               -  Males or females ≥ 50 years of age

               -  Meet clinical criteria for dementia due to probable AD

               -  MMSE ≥ 16 and ≤ 26

          -  Possible AD Subject

               -  Males or females ≥ 50 years of age

               -  Meet clinical criteria for dementia due to possible AD

               -  MMSE ≥ 16 and ≤ 26

          -  MCI Subject

               -  Males or females ≥ 60 years of age with cognitive impairment (not dementia)

               -  MMSE &gt;24 and &lt;29

          -  At Risk Elderly Subject

               -  Cognitively normal males or females that are known ApoE4 carriers and ≥ 75 years
                  of age

               -  MMSE ≥ 27

        Exclusion Criteria:

          -  Have had or currently have a diagnosis of neurodegenerative disorders other than AD

          -  Have a current serious or unstable illness that could interfere with completion of the
             study

          -  Subject has a known brain lesion, pathology or traumatic brain injury

          -  Have received or participated in a trial with investigational medications in the past
             30 days

          -  Have had a radiopharmaceutical imaging or treatment procedure within 7 days of study
             imaging session

          -  Females of childbearing potential who are not surgically sterile, not refraining from
             sexual activity or not using reliable methods of contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Chair</role>
    <affiliation>Avid Radiopharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, Johnson KA, Mathis CA, Minhas D, Pontecorvo MJ, Rowe CC, Skovronsky DM, Mintun MA. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015 Jan;11(1):1-15.e1-4. doi: 10.1016/j.jalz.2014.07.003. Epub 2014 Oct 28.</citation>
    <PMID>25443857</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2014</study_first_submitted>
  <study_first_submitted_qc>April 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2014</study_first_posted>
  <results_first_submitted>September 30, 2016</results_first_submitted>
  <results_first_submitted_qc>January 20, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 9, 2017</results_first_posted>
  <last_update_submitted>January 20, 2017</last_update_submitted>
  <last_update_submitted_qc>January 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First subject enrolled: 14 April 2014; Last subject completed: 18 September 2015</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Clincally Diagnosed AD</title>
          <description>Patients meeting clinical criteria for dementia due to probable Alzheimer's Disease (AD)</description>
        </group>
        <group group_id="P2">
          <title>Possible AD</title>
          <description>Patients meeting clinical criteria for dementia due to possible Alzheimer's Disease</description>
        </group>
        <group group_id="P3">
          <title>Mild Cognitive Impairment (MCI)</title>
          <description>Patients with a clinical diagnosis of Mild Cognitive Impairment (MCI) and not dementia. Age is 60 years or greater</description>
        </group>
        <group group_id="P4">
          <title>At Risk Elderly</title>
          <description>Elderly patients, 75 years or older, who are known ApoE4 gene carriers, and cognitively normal</description>
        </group>
        <group group_id="P5">
          <title>Young Healthy Controls (YHC)</title>
          <description>Cognitively normal young subjects between 21 and 45 years of age (inclusive)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects receiving at least one dose of florbetapir</population>
      <group_list>
        <group group_id="B1">
          <title>Clincally Diagnosed AD</title>
          <description>Patients meeting clinical criteria for dementia due to probable Alzheimer's Disease (AD)</description>
        </group>
        <group group_id="B2">
          <title>Possible AD</title>
          <description>Patients meeting clinical criteria for dementia due to possible Alzheimer's Disease</description>
        </group>
        <group group_id="B3">
          <title>Mild Cognitive Impairment (MCI)</title>
          <description>Patients with a clinical diagnosis of Mild Cognitive Impairment (MCI) and not dementia. Age is 60 years or greater</description>
        </group>
        <group group_id="B4">
          <title>At Risk Elderly</title>
          <description>Elderly patients, 75 years or older, who are known ApoE4 gene carriers, and cognitively normal</description>
        </group>
        <group group_id="B5">
          <title>Young Healthy Controls (YHC)</title>
          <description>Cognitively normal young subjects between 21 and 45 years of age (inclusive)</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="10"/>
            <count group_id="B6" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.2" spread="4.94"/>
                    <measurement group_id="B2" value="66" spread="4.76"/>
                    <measurement group_id="B3" value="79.9" spread="8.47"/>
                    <measurement group_id="B4" value="79.3" spread="2.5"/>
                    <measurement group_id="B5" value="27.3" spread="4.83"/>
                    <measurement group_id="B6" value="60.1" spread="22.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mini Mental Status Exam</title>
          <description>Mini Mental Status Exam (MMSE) is a brief instrument used to assess cognitive function in elderly patients. The instrument is divided into 2 sections. The first section measures orientation, memory, and attention. The maximum score for the first section is 21. The second section tests the ability of the patient to name objects, follow verbal and written commands, write a sentence, and copy figures. The maximum score for the second section is 9. The range for the total MMSE score is 0 to 30. Higher scores indicate higher cognitive function.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.7" spread="2.45"/>
                    <measurement group_id="B2" value="21.8" spread="4.92"/>
                    <measurement group_id="B3" value="26.4" spread="1.27"/>
                    <measurement group_id="B4" value="29.3" spread="0.96"/>
                    <measurement group_id="B5" value="29.5" spread="0.53"/>
                    <measurement group_id="B6" value="26.3" spread="3.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Florbetapir SUVr Conversion to Centiloid Units</title>
        <description>Conversion of florbetapir (18F) positron emission tomography (PET) standard uptake value ratio (SUVr) to Centiloid units. The Centiloid is anchored at values of 0 and 100 corresponding to the median Pittsburgh Compound B (11C-PiB) SUVr value for a representative group of young (&lt;45) cognitively and medically healthy control subjects (YHC) and the median SUVr value for a representative group of 11C-PiB positive patients diagnosed with Alzheimer’s disease, respectively. A cortical average to cerebellum SUVr was used for this outcome measure.</description>
        <time_frame>up to 70 minutes post injection</time_frame>
        <population>All participants receiving both a florbetapir and a PiB scan per protocol. One subject in the possible AD group did not complete a florbetapir scan due to excessive movement. One subject in the at risk elderly group elected to leave the study before the second PET scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Clincally Diagnosed AD</title>
            <description>Patients meeting clinical criteria for dementia due to probable Alzheimer's Disease (AD)</description>
          </group>
          <group group_id="O2">
            <title>Possible AD</title>
            <description>Patients meeting clinical criteria for dementia due to possible Alzheimer's Disease</description>
          </group>
          <group group_id="O3">
            <title>Mild Cognitive Impairment (MCI)</title>
            <description>Patients with a clinical diagnosis of Mild Cognitive Impairment (MCI) and not dementia. Age is 60 years or greater</description>
          </group>
          <group group_id="O4">
            <title>At Risk Elderly</title>
            <description>Elderly patients, 75 years or older, who are known ApoE4 gene carriers, and cognitively normal</description>
          </group>
          <group group_id="O5">
            <title>Young Healthy Controls (YHC)</title>
            <description>Cognitively normal young subjects between 21 and 45 years of age (inclusive)</description>
          </group>
        </group_list>
        <measure>
          <title>Florbetapir SUVr Conversion to Centiloid Units</title>
          <description>Conversion of florbetapir (18F) positron emission tomography (PET) standard uptake value ratio (SUVr) to Centiloid units. The Centiloid is anchored at values of 0 and 100 corresponding to the median Pittsburgh Compound B (11C-PiB) SUVr value for a representative group of young (&lt;45) cognitively and medically healthy control subjects (YHC) and the median SUVr value for a representative group of 11C-PiB positive patients diagnosed with Alzheimer’s disease, respectively. A cortical average to cerebellum SUVr was used for this outcome measure.</description>
          <population>All participants receiving both a florbetapir and a PiB scan per protocol. One subject in the possible AD group did not complete a florbetapir scan due to excessive movement. One subject in the at risk elderly group elected to leave the study before the second PET scan.</population>
          <units>centiloid</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.44" spread="45.623"/>
                    <measurement group_id="O2" value="50.75" spread="60.383"/>
                    <measurement group_id="O3" value="81.19" spread="66.357"/>
                    <measurement group_id="O4" value="14.93" spread="35.885"/>
                    <measurement group_id="O5" value="5.24" spread="11.981"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of Florbetapir (18F) Centiloid and 11C-PiB Centiloid</title>
        <description>Correlation coefficient between 11C-PiB and florbetapir (18F) SUVr as converted to centiloid units. The Centiloid is anchored at values of 0 and 100 corresponding to the median Pittsburgh Compound B (11C-PiB) SUVr value for a representative group of young (&lt;45) cognitively and medically healthy control subjects (YHC) and the median SUVr value for a representative group of 11C-PiB positive patients diagnosed with Alzheimer’s disease, respectively. A cortical average to cerebellum SUVr was used for this outcome measure.</description>
        <time_frame>up to 70 minutes post injection</time_frame>
        <population>All participants receiving both a florbetapir and a PiB scan per protocol. One subject in the possible AD group did not complete the florbetapir scan due to excessive movement. One subject in the at risk elderly group elected to leave the study before the second PET scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Clincally Diagnosed AD</title>
            <description>Patients meeting clinical criteria for dementia due to probable Alzheimer's Disease (AD)</description>
          </group>
          <group group_id="O2">
            <title>Possible AD</title>
            <description>Patients meeting clinical criteria for dementia due to possible Alzheimer's Disease</description>
          </group>
          <group group_id="O3">
            <title>Mild Cognitive Impairment (MCI)</title>
            <description>Patients with a clinical diagnosis of Mild Cognitive Impairment (MCI) and not dementia. Age is 60 years or greater</description>
          </group>
          <group group_id="O4">
            <title>At Risk Elderly</title>
            <description>Elderly patients, 75 years or older, who are known ApoE4 gene carriers, and cognitively normal</description>
          </group>
          <group group_id="O5">
            <title>Young Healthy Controls (YHC)</title>
            <description>Cognitively normal young subjects between 21 and 45 years of age (inclusive)</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of Florbetapir (18F) Centiloid and 11C-PiB Centiloid</title>
          <description>Correlation coefficient between 11C-PiB and florbetapir (18F) SUVr as converted to centiloid units. The Centiloid is anchored at values of 0 and 100 corresponding to the median Pittsburgh Compound B (11C-PiB) SUVr value for a representative group of young (&lt;45) cognitively and medically healthy control subjects (YHC) and the median SUVr value for a representative group of 11C-PiB positive patients diagnosed with Alzheimer’s disease, respectively. A cortical average to cerebellum SUVr was used for this outcome measure.</description>
          <population>All participants receiving both a florbetapir and a PiB scan per protocol. One subject in the possible AD group did not complete the florbetapir scan due to excessive movement. One subject in the at risk elderly group elected to leave the study before the second PET scan.</population>
          <units>centiloid</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Florbetapir</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.44" spread="45.623"/>
                    <measurement group_id="O2" value="50.75" spread="60.383"/>
                    <measurement group_id="O3" value="81.19" spread="66.357"/>
                    <measurement group_id="O4" value="14.93" spread="35.885"/>
                    <measurement group_id="O5" value="5.24" spread="11.981"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11C-PiB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.18" spread="41.105"/>
                    <measurement group_id="O2" value="54.52" spread="56.511"/>
                    <measurement group_id="O3" value="74.33" spread="57.597"/>
                    <measurement group_id="O4" value="26.39" spread="37.464"/>
                    <measurement group_id="O5" value="0.73" spread="2.414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>R squared</param_type>
            <param_value>0.907</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Variability of PET Images in Young Healthy Control Subjects.</title>
        <description>Coefficient of variation for 11C-PiB and florbetapir (18F) SUVr. A cortical average to cerebellum SUVr was used for this outcome measure.</description>
        <time_frame>up to 70 minutes post injection</time_frame>
        <population>Young healthy controls enrolled in the study</population>
        <group_list>
          <group group_id="O1">
            <title>PiB SUVR Variability</title>
            <description>Variability of standardized uptake value ratio (SUVR) for PiB scans in young healthy controls</description>
          </group>
          <group group_id="O2">
            <title>Florbetapir SUVR Variability</title>
            <description>Variability of standardized uptake value ratio (SUVR) for florbetapir scans in young healthy controls</description>
          </group>
        </group_list>
        <measure>
          <title>Variability of PET Images in Young Healthy Control Subjects.</title>
          <description>Coefficient of variation for 11C-PiB and florbetapir (18F) SUVr. A cortical average to cerebellum SUVr was used for this outcome measure.</description>
          <population>Young healthy controls enrolled in the study</population>
          <units>SUVr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread="0.026"/>
                    <measurement group_id="O2" value="0.98" spread="0.066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Coefficient of Variation</param_type>
            <param_value>2.53</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Coefficient of Variation</param_type>
            <param_value>6.69</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>within 48 hours of scan as noted by group title</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Florbetapir Only</title>
          <description>Events occurring within 48 hours following florbetapir scans only</description>
        </group>
        <group group_id="E2">
          <title>PiB Only</title>
          <description>Events occurring within 48 hours of PiB scans only</description>
        </group>
        <group group_id="E3">
          <title>Both</title>
          <description>Events occurring within 48 hours of both florbetapir and PiB scans</description>
        </group>
        <group group_id="E4">
          <title>Total</title>
          <description>Events following Florbetapir (florbetapir only and both)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Avid Radiopharmaceuticals, Inc.</organization>
      <phone>215-298-0700</phone>
      <email>clinicaloperations@avidrp.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

